Page last updated: 2024-11-01

niceritrol and Hyperlipoproteinemia Type III

niceritrol has been researched along with Hyperlipoproteinemia Type III in 1 studies

Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kibata, M1
Ishida, M1
Asano, K1
Uehara, H1
Saito, K1
Fuchimoto, T1
Ugaki, K1
Murakami, H1
Matoba, K1
Kotakemori, Y1
Shirai, K1
Yoshioka, H1
Nanba, M1
Yasuda, M1
Ishizaki, M1
Kitagawa, N1
Ikejiri, K1
Inohara, R1
Lee, BJ1
Saino, S1
Sakado, J1
Matuzaka, H1
Numata, K1
Mandai, M1
Miyake, K1
Nakamura, K1

Other Studies

1 other study available for niceritrol and Hyperlipoproteinemia Type III

ArticleYear
Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.
    Atherosclerosis, 1980, Volume: 37, Issue:3

    Topics: Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hypolipide

1980